Ikena Oncology (NASDAQ:IKNA – Get Rating) and SPK Acquisition (NASDAQ:SPK – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Insider and Institutional Ownership

72.4% of Ikena Oncology shares are owned by institutional investors. Comparatively, 19.6% of SPK Acquisition shares are owned by institutional investors. 4.8% of Ikena Oncology shares are owned by company insiders. Comparatively, 22.4% of SPK Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Get Ikena Oncology alerts:

Earnings and Valuation

This table compares Ikena Oncology and SPK Acquisition's gross revenue, earnings per share and valuation.

SPK Acquisition has lower revenue, but higher earnings than Ikena Oncology.

Risk & Volatility

Ikena Oncology has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, SPK Acquisition has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ikena Oncology and SPK Acquisition, as provided by MarketBeat.

Ikena Oncology presently has a consensus target price of $19.00, indicating a potential upside of 614.29%. Given Ikena Oncology's higher possible upside, analysts plainly believe Ikena Oncology is more favorable than SPK Acquisition.

Profitability

This table compares Ikena Oncology and SPK Acquisition's net margins, return on equity and return on assets.

Summary

Ikena Oncology beats SPK Acquisition on 5 of the 9 factors compared between the two stocks.

About Ikena Oncology

(Get Rating)

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

About SPK Acquisition

(Get Rating)

SPK Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on operating businesses in the telecommunications, media, and technology sectors in Asia. The company was incorporated in 2020 and is based in Shanghai, China.

Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.